However, considering a significant risk of recurrent HCC after curative liver resection, some safer NSAIDs, such as selective COX-2 inhibitors, applied as chemopreventive agents in this high-risk population might be justified. The gene discussed is PTGS2; the disease is hepatocellular carcinoma.